Combined Lifestyle Modification and Metformin in Obese Patients with Polycystic Ovary Syndrome: A Randomized, Placebo-controlled, Double-blind Multicentre Study

Tang, Thomas; Glanville, Julie; Hayden, Catherine M.; White, Davinia; Barth, Julian H.; Balen, Adam

doi:10.1097/01.ogx.0000197800.07214.dc

Cited by 97 publications

(143 citation statements)

References 55 publications

Supporting

Mentioning

130

Contrasting

Unclassified

Order By: Relevance

“…Also in the present study lipid profile improved after metformin therapy and these data partially agree with Rautio et al (37) who demonstrated beneficial effects not only for HDL levels but also for TC and TG; however, other contrasting evidences were reported on the same issue, showing some improvement (38) or no difference (39) in lipid profile after metformin therapy in PCOS women.…”

Section: Discussionsupporting

confidence: 76%

Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study

Orio¹,

Manguso²,

Biase³

et al. 2007

European Journal of Endocrinology

View full text Add to dashboard Cite

Introduction: Polycystic ovary syndrome (PCOS) is a common disorder associated with a wide range of endocrine and metabolic abnormalities. Low-grade chronic inflammation is a related complication recently observed in PCOS. Increased white blood cell (WBC) count was previously reported in PCOS women. Objective: To evaluate the effects of six months metformin administration on WBC count in PCOS women. Patients and methods: Fifty normal-weight PCOS women without additional metabolic or cardiovascular diseases were enrolled and treated with metformin (850 mg twice daily) for 6 months in a prospective baseline-controlled clinical study. At baseline and after treatment, WBC count and C-reactive protein (CRP) were evaluated in each patient. The whole hormonal profile, serum insulin and glucose levels (at fasting and during a 75 g 2-h oral glucose tolerance test), serum lipid profile were also assessed. Results: A significant difference was observed in WBC count (7050G552 vs 6080G577 cell/mm

show abstract

Section: Discussionsupporting

confidence: 76%

Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study

Orio¹,

Manguso²,

Biase³

et al. 2007

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Patients in both groups showed similar improvements in their menstrual cyclicity [23] with 52.2% improvement in the metformin group and 58.1% in the placebo group. Significant weight loss was achieved in both groups.…”

Section: Discussionmentioning

confidence: 53%

“…The randomized, prospective, multicenter study conducted by Tang and colleagues [23] assessed whether lifestyle changes alone or in combination with metformin (an insulin sensitizer) are associated with superior endocrine, anthropometric, and menstrual cycle characteristics among PCOS women.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of metformin & myoinositol & life style modification in patients of polycystic ovarian disease (PCOD)

Awalekar¹,

Awalekar²,

Jadhav³

et al. 2015

Int Jour of Biomed Res

View full text Add to dashboard Cite

show abstract

“…90 Details of trials of at least 6 months' duration are shown in Table 5. 81,[91][92][93][94] In general, these were well designed, randomized studies (evidence level A). However, one study 92 randomized patients to one of two doses of metformin, without a non-metformin control group, and was thus categorized as evidence level C for the purposes of this review.…”

Section: Polycystic Ovary Syndromementioning

confidence: 99%

Metformin and body weight

2007

View full text Add to dashboard Cite

Most patients with type 2 diabetes are overweight or obese, overweight or obesity increases the risk of developing type 2 diabetes and obesity per se is strongly associated with multiple cardiometabolic risk factors. However, many antidiabetic treatments increase body weight. The oral antidiabetic agent, metformin, has been evaluated in hundreds of clinical studies in diverse patient populations during approximately five decades of clinical use. This review summarizes the effects of metformin on body weight, with special reference to studies of longer duration (X6 months) as both diabetes and obesity are long-term conditions. Approximately half of studies in drug-naive type 2 diabetic patients demonstrated significant weight loss with metformin compared with baseline or comparator drugs, although pooled analyses have suggested no significant effect versus placebo. Similarly, metformin has been shown to induce weight loss in obese nondiabetic populations, although studies of long duration in this population are scarce. Metformin does appear to mitigate the adverse effects of insulin on body weight. The weight-neutral or weight-sparing effects of metformin constitute a therapeutic advantage in diabetes management where other first-line oral antidiabetic treatments often promote clinically significant weight gain.

show abstract

Combined Lifestyle Modification and Metformin in Obese Patients with Polycystic Ovary Syndrome: A Randomized, Placebo-controlled, Double-blind Multicentre Study

Cited by 97 publications

References 55 publications

Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study

Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study

Effect of metformin & myoinositol & life style modification in patients of polycystic ovarian disease (PCOD)

Metformin and body weight

Contact Info

Product

Resources

About